{
    "clinical_study": {
        "@rank": "90745", 
        "acronym": "MispheC", 
        "arm_group": {
            "arm_group_label": "Therasphere\u00ae", 
            "arm_group_type": "Experimental", 
            "description": "Therasphere\u00ae in association with Gemcitabine and Cisplatin"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess efficacy and tolerance of intra-hepatic\n      administration of Yttrium 90-labelled microsphere (Theraspheres\u00ae, Nordion) in association\n      with intravenous chemotherapy with Gemcitabin and Cisplatin for the treatment of\n      intra-hepatic cholangiocarcinoma."
        }, 
        "brief_title": "Efficacy Study of Intra-hepatic Administration of Therasphere\u00ae in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Cholangiocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Cholangiocarcinoma", 
                "Liver Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed intra-hepatic cholangiocarcinoma.\n\n          2. Measurable target of at least 2 cm diameter.\n\n          3. Healthy liver or cirrhosis CHILD < B8.\n\n          4. WHO-PS: 0-1.\n\n          5. Age \u2265 18 years.\n\n          6. Non-Metastatic disease in extra-hepatic (are permitted: local lymph nodes < 3 cm,\n             less than 5 lung nodes < 11 mm).\n\n          7. Creatinine clearance (calculated with Cockcroft and Gault formula) \u2265 55 ml/min,\n             polymorphonuclear neutrophils \u2265 1500 G/L, platelets \u2265 80 G/L, prothrombin \u2265 40% (INR\n             \u2264 2.3), serum albumin \u2265 28 g/l, serum bilirubin \u2264 3 x LSN.\n\n          8. Pregnancy test: negative for women of childbearing potential.\n\n          9. Reliable contraception for a childbearing couple, men and woman must have an reliable\n             contraception during the treatment and until 6 months following the end of the\n             treatment by chemotherapy\n\n         10. Signed informed consent form.\n\n         11. Patient with national health insurance.\n\n        Exclusion Criteria:\n\n          1. Pancreas cancer or duodenum cancer invading the bile duct or ampullary cancer.\n             Cholangiocarcinoma of the bile ducts: hilar, main duct, gallbladder.\n\n          2. Extra-hepatic metastasis (including local lymph nodes measuring > 30 mm).\n\n          3. Primary sclerosing cholangitis.\n\n          4. History of chemoembolization or radioembolization.\n\n          5. Cirrhose CHILD > B7\n\n          6. Portal vein trunk tumoral thrombosis\n\n          7. History of hepato-biliary neo adjuvant or palliative chemotherapy and/or\n             radiotherapy.\n\n          8. Contra indication of Gemcitabine and/or Cisplatin.\n\n          9. Other invasive active cancer, excepting in situ cervical cancer and basocellular or\n             spino cellular skin cancer treated adequately. Any history of cancer not considered\n             as completely cured for at least one year.\n\n         10. Technical failure of the diagnostic arteriography.\n\n         11. Extra hepatic uptake on the pre-therapeutic scintigraphy not manageable with an\n             arteriography.\n\n         12. Dosimetry study predicting lung exposure > 30 Gy.\n\n         13. Any unstable medical history (diabetes, hypertension \u2026).\n\n         14. History of organ transplant.\n\n         15. Symptomatic grade 1 angina pectoris or grade \u2265 2 angina pectoris.\n\n         16. An evolutive neuropathy.\n\n         17. Patient who already has been involved in a clinical trial with drug intake, whether\n             this drug was experimental or not, within 30 days before.\n\n         18. Pregnant patient or patient with breastfeeding.\n\n         19. Patient under administrative supervision.\n\n         20. Regular follow-up impossible for various reasons (psychological, familial,\n             economical, and social)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912053", 
            "org_study_id": "2012-EB-CHOL-Th", 
            "secondary_id": [
                "2012-001213-16", 
                "A121007-71"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Therasphere\u00ae", 
            "description": "Therasphere\u00ae is a radioelement", 
            "intervention_name": "Therasphere\u00ae in association with Gemcitabine and Cisplatin", 
            "intervention_type": "Radiation", 
            "other_name": "90-Yttrium theraspheres"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Intra-hepatic Cholangiocarcinoma treatment", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Olivier Frages, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92118"
                    }, 
                    "name": "H\u00f4pital Beaujon - Service de Chirurgie"
                }, 
                "investigator": {
                    "last_name": "Olivier Farges, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Philippe Compagnon, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "H\u00f4pital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Philippe Compagnon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eric ASSENAT, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "H\u00f4pital saint-Eloi"
                }, 
                "investigator": {
                    "last_name": "Eric ASSENAT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Laurence Chone, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54000"
                    }, 
                    "name": "CHU Nancy - H\u00f4pital Brabois"
                }, 
                "investigator": {
                    "last_name": "Laurence Chone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fran\u00e7oise Kreaber-Brodere, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU- Hotel Dieu"
                }, 
                "investigator": {
                    "last_name": "Yann Touchefeu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "e.boucher@rennes.unicancer.fr", 
                    "last_name": "Eveline Boucher, MD", 
                    "phone": "+33(0)299253180"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35042"
                    }, 
                    "name": "Centre Eugene Marquis"
                }, 
                "investigator": {
                    "last_name": "Eveline Boucher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Malka, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Institut Gustave Roussy - Unit\u00e9 de Gastro-Ent\u00e9rologie"
                }, 
                "investigator": {
                    "last_name": "David Malka, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere\u00ae, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line.", 
        "overall_contact": {
            "email": "e.boucher@rennes.unicancer.fr", 
            "last_name": "Eveline Boucher, MD", 
            "phone": "+33(0)299253180"
        }, 
        "overall_official": {
            "affiliation": "Centre Eugene Marquis", 
            "last_name": "Eveline Boucher, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation according RECIST 1.1 criteria. Rate will be reassessed every 8 weeks", 
            "measure": "Radiological response rate to the treatment with the association of chemotherapy and radioembolization", 
            "safety_issue": "No", 
            "time_frame": "3 months after radioembolization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912053"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Grade 3-4 toxicity appearance.Time between 1st treatment administration and date of 1st appearance of a grade 3-4 toxicity or date of last toxicities assessment in case no grade 3-4 toxicity", 
                "measure": "Tolerance of intra-hepatic administration of Yttrium 90-labelled microspheres in association with intravenous chemotherapy with Gemcitabine and Cisplatin assessed according NCI/CTC AE version 4.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to  24 months"
            }, 
            {
                "description": "Markers will be analysed every 8 weeks during treatment period and if applicable every 12 weeks after surgery", 
                "measure": "Tumor markers changes (CA19.9, CEA and AFP)", 
                "safety_issue": "No", 
                "time_frame": "Up to  24 months"
            }, 
            {
                "description": "every 8 weeks and every 12 weeks after surgery if applicable", 
                "measure": "Radiological response rate by the CHOI criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to  24 months"
            }, 
            {
                "measure": "Change in metabolic activity measured by TEP", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in metabolic activity 15 and 24 weeks after last treatment by microspheres"
            }, 
            {
                "description": "Every 8 weeks during treatment and every 12 weeks after surgery if applicable", 
                "measure": "Changes of liver volume", 
                "safety_issue": "No", 
                "time_frame": "Up to  24 months"
            }, 
            {
                "description": "Data obtained from SPECT/CT performed at each hepatic scintigraphy", 
                "measure": "Tumoral and non-tumoral dosimetric assessment of the liver", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "source": "Center Eugene Marquis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Center Eugene Marquis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}